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Abstract With the recent change of the botanical code
for the names of algae, fungi, and plants, fungi are no
longer allowed to have multiple names for their different
reproductive stages. Here we discuss that under the new
nomenclatural rules and for taxonomic stability, Fusarium
is to be preferred above names for some of its known
sexual stages like Haemonectria and Gibberella. The
genus Fusarium contains emerging etiological agents of
disease ranging from onychomycoses, skin and eye-
infections, to deep localized and disseminated infections.
Deep infections occur nearly exclusively in immunocom-
promised patients, while remaining infections primarily
affect healthy individuals. Within the large genus, at least
seven species complexes comprising multiple species
have been implicated in human and animal infections.
In this review we give an overview of currently known
opportunistic Fusarium species and the infections they
cause.
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An Introduction to Fusarium Taxonomy
For centuries, systematics has been based on morphological
characteristics, and hence fungi were grouped mostly accord-
ing to visible (reproductive) structures. As many fungal spe-
cies exhibit both asexual and sexual reproduction—which
may occur independently from each other—they were
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allowed to carry separate names for different parts of the life
cycle. DNA analysis has become indispensable, which has led
to discoveries of genetic links between previously separated
entities. Where in the past, anamorphic and teleomorphic
names clarified relationships between species, they have be-
come rather confusing today.
Due to recent changes in the International Code of
Nomenclature for Algae, Fungi, and Plants, as of January
2013 every fungal species is allowed to have only a single
name [1]. Furthermore, where formerly, preference would be
given to the sexual name over the asexual one, exceptions are
now allowed, e.g., for sake of preservation of older names, but
also for widely used genus and species names. A huge task
now lies in the determination of what is the best name for each
species.
For Fusarium, a plea has been made to conserve the name
Fusarium above all linked teleomorphic names like
Heamonectria and Gibberella [2•]. For nomenclatural stabil-
ity, assembled experts in the fields of plant pathology, myco-
toxins, and human and animal pathology preferred to maintain
the best known—or perhaps we should say, for its variety of
deleterious effects, most infamously known—name:
Fusarium. Hence, use of the name Fusarium is unproblemat-
ic, but generic borderlines are yet to be determined. For
medically relevant fungi, an extra plea has been made to
reduce the number of unnecessary name changes and to keep
well-known names as stable as possible [3•].
In this era of genomics, it is well-accepted to use a multi-
locus sequence typing (MLST) approach in combination with
the genealogical concordance phylogenetic species recogni-
tion (GCPSR) principle [4] rather than morphology to recog-
nize species and to sort out their relationships. For many of the
morphologically defined Fusarium species, we know from
MLST-GCPSR that we are dealing with species complexes
of morphologically (nearly) indistinguishable siblings rather
than with single species. Fusarium was one of the first fungal
groups where the term ‘species complex’was commonly used
for closely related species [e.g.,[ 7, 8]. Within such a species
complex different MLST-haplotypes can be recognized that,
after careful consideration, may be established as separate
species. An example of this is the recent recognition of
F. keratoplasticum and F. petroliphilum, two opportunistic
pathogens in the Fusarium solani species complex [5].
Geiser et al. [2•] in their proposal to preserve the genus
Fusarium in a robust way maintain a wide definition of the
genus Fusarium (Fig. 1A; node F1 is the hypothetical ancestor
for the entire genus). In this way, the terminal Fusarium clade
comprises at least 20 strongly supported species complexes
and nine monotypic lineages [6], including seven Fusarium
species complexes associated with described cases of human
infections: the F. dimerum species complex (FDSC), the
F. solani species complex (FSSC), the Fusarium oxysporum
species complex (FOSC), the F. fujikuroi species complex
(FFSC, encompassing F. proliferatum and F. verticillioides),
the F. incarnatum-equiseti species complex (FIESC), the
F. chlamydosporum species complex (FCSC), and the com-
plex including F. sporotrichioides (FSAMSC). Only a few
other Fusarium species outside these species (complexes)
have occasionally been implicated in human or mammal
infections. In this review we will use this broadest definition
(Fig. 1A-block A) of the genus Fusarium.
Alternatively, a more narrow definition of the genus
Fusarium could be made, placing the border of the genus,
for instance, at nodes F2 or F3 in Fig. 1A. Under these
scenarios there are two species complexes that include human
opportunists and that would then need reallocation into new
genera: The first group would be FDSC (Fig. 1A-block D),
including F. dimerum, F. delphinoides, and others. The other
option would exclude also the FSSC (Fig. 1A-block C), which
would exclude the largest and most important group with
respect incidence: best known as F. solani sensu lato, leaving
everything linked with a Gibberella-like teleomorphic stage
(Fig. 1A-block A) as core-Fusarium species. Nodes F1, F2,
and F3 receive different levels of support based on phyloge-
netic analyses like maximum likelihood, maximum parsimo-
ny, and Bayesian analysis, but as none of these are 100 %
conclusive, the definition of Fusarium is kept as broad as
possible [2•, 6].
Identification of Fusarium Species
The most typical feature of the genus Fusarium is its unique
spindle- or canoe-shaped, multicellular macroconidia.
However, these macroconidia are not always present, and
differently shaped, single-celled or multicellular micro- and/
or mesoconidia may also be formed as well as
(pseudo-)chlamydospores. The shape of conidiophores, i.e.,
the structures on which conidia are formed, may differ be-
tween species. Some species are homothallic and produce
fruiting bodies with ascospores, while heterothallic species
need a suitable partner to produce such structures [7]. Keys
have been published for the recognition of clinical Fusarium
species [e.g.,[ 4, 83]. These keys are based on morphological
structures and require expert training. Fungi have to be grown
on standardized, specialized media, and the formation of
distinguishing features may require up to 6–8 weeks, render-
ing precise identification clinically redundant. Besides, mor-
phological recognition of Fusarium species in a hospital set-
ting is often impossible by degeneration of colony morphol-
ogy or by conversion to a ‘pionnotal’ phenotype [8].
For DNA-based identification of fungi in general, the
barcoding and recognition region is the internal transcribed
sequence (ITS) region. However, for Fusarium spp. this re-
gion is too conserved and may not even distinguish between
species complexes, let alone down to the species level. For
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identification of molecular siblings, the Translation elongation
factor 1-alpha (TEF-1α) region, or RNA polymerase II sub-
units 1 and 2 (RPB1 and RPB2) are especially recommended
[9]. A curated database allows for the comparison of found
sequences with well-identifiedFusarium isolates (http://www.
cbs.knaw.nl/fusarium/) [9].
Molecular identification techniques of Fusarium
based on DNA polymorphisms have been developed
for use on pure cultures. Direct sequencing of DNA
in patient samples also provides an option [10].
Detection techniques include reverse line blotting
(RLB) [11], loop-mediated isothermal amplification
(LAMP) [12], or rolling circle amplification (RCA)
[13]. Besides, multiplex DNA screenings have been
developed. These methods may combine (tandem) po-
lymerase chain reactions (PCR) reactions with flow
cytometry and/or microarrays [14–18].
Other diagnostic tools in development focus on spe-
cific peptides or other metabolites produced by fungi. In
particular, matrix-assisted laser desorption ionization
time-of-flight (Maldi-TOF) mass spectrometry is being
explored [19–21]. This technique is still restricted to the
identification of pure cultures, while patient samples
are still problematic.
Emerging Opportunists—now and in the Future
Members of the genus Fusarium have been involved in infec-
tions ranging from localized (nail, skin, eye, or other location),
mainly in immunocompetent hosts, to disseminated infections in
immunocompromised patients (for a review see e.g., [8] and
below). Over the years, the number of case reports on fusarioses
both in immunocompetent and compromised hosts has steadily
increased (Fig. 1B; data until October 2013 from PubMed http://
www.ncbi.nlm.nih.gov/pubmed). About 40 % of these reports
were due to members of the FSSC, while the FOSC was
involved in approximately 20 % of these reports (Fig. 1C).
Species distributions in the different types of fusarioses
have to be concluded from the few population studies done
so far. Three studies focused on onychomycoses and skin
infections in Italy [22], Switzerland [23], and Colombia
Fig. 1 a Cladogram representation of the (provisional) genus Fusarium
[2•, 6] with the location of Fusarium species (complexes) reported mul-
tiple times to have been involved in human infections (black) or just once
(grey). b-c These Fusarium spp. are emerging fungal pathogens indicated
by the increasing number of case reports on fusarioses over the years
(Pubmed http://www.ncbi.nlm.nih.gov/pubmed data until October 2013).
b Both the numbers of infections in healthy individuals as well as in
immunocompromised patients have increased. c The majority of case
reports were caused by members of the Fusarium solani species complex,
followed by members of the Fusarium oxysporum species complex and
other species
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[24], respectively (Table 1). Etiological agents belonged to
FSSC causing 31–82 % and FOSC 4–56 % of infections,
while members of the FFSC caused 2–37%; only in one study
a single member of the FDSC was found. The prevalence of
onychomycoses in humans lies in the range of 5–15 % of the
adult population [29–31]. Many of these are caused by
Candida or dermatophytes, but some studies indicate that
Fusarium spp. can make up to 10–15 % of the cases [van
Diepeningen unpublished results, 20]. Suggested predispos-
ing factors for onychomycosis in general include increasing
age, but also immunosuppression, poor peripheral circulation,
trauma, and tinea pedis [29].
Two studies focused on eye infections caused by Fusarium
in India [25] and Mexico [26] reported that 75–82 % of the
infections are caused by FSSC, 9–12 % by FDSC, and then
occasionally by members of FOSC, FFSC, and FIESC. Fungal
keratitis is often linked with trauma, especially with vegetable
or other organic matter. The infection is more common in
tropical areas and in areas with a relatively large agrarian
population. However, prevalence data are still approximate.
Lortholary et al. [27] focused on disseminated fusarioses in
the immunocompromised host, where approximately one-third is
caused by FSSC, another third by FFSC, and the remainder by
FOSC, FDSC, or rarely by FIESC. Limited data exist on the
prevalence of each species. Girmenia et al. [32] estimated a
prevalence of 0.06 % of fusarioses in patients with acute leuke-
mia in Italy, while Nucci et al. [33] noted an increase in Brazil
from 0.86 to 10.23 cases of fusariosis/1,000 hospital admissions
in haemato-oncology wards. The one-year cumulative incidence
of fusariosis in AML/MDS, allogeneic HCT, and autologous
HCT patients proved to be 5.2, 3.8, and 0.6 % (p=0.01), respec-
tively [34]. Disseminated infection in general seems to occur
especially in haemato-oncological patients (Table 2). The
numbers of cases in patients after a solid-organ transplant, HIV,
or other reasons for immunodeficiency are much lower.
Fusarioses in SOT recipients tend to remain localized, occur later
in the post-transplantation period, and have a better outcome [86].
With ever-rising numbers of immunocompromised patients
due to better treatment and survival rates, and also through better
prophylaxis against Candida and Aspergillus, the prevalence of
invasive fusariosis may rise further in the future. Primary cuta-
neous infections often prove to be the portal of entry for a
disseminated fusariosis [33, 87]. In return, disseminated infec-
tions lead to secondary cutaneous lesions [e.g., [88].
From a global comparison of the different studies of
fusarioses, it can be deduced that there are regional differences
in prevalent etiological agents (Table 1). For example, in
Colombia the numbers of onychomycoses caused by FSSC
are higher than in Europe [22–24]. Furthermore, some species
complexes seem to be more often involved in certain types of
infections; for instance, members of FFSC are relatively often
involved in disseminated infections [27]. While members of
FDSC seem to be more often involved in eye and disseminat-
ed infections than in onychomycoses.
Clinical Spectra of Fusarium Species
The Fusarium solani species complex (FSSC) globally is the
most common group encountered in human infections. It
contains sixty or more haplotypes, some of which are pre-
dominant in patients [28, 89]. Of these, F. falciforme,
F. keratoplasticum, F. lichenicola, and F. petroliphilum have
been treated as separate species within FSSC, capable of
human infection. Reported cases by members of FSSC range
from onychomycosis to disseminated infection (see Table 2
for references). However, in most of the published cases no
FSSC haplotypes were mentioned and sequences were not
available. For this reason, they are listed in Table 2 as infec-
tions by F. solani sensu lato. Disseminated infections in
patients with underlying diseases other than haemato-
oncological disorders are rare, although a few cases of infec-
tion after solid organ transplant [40, 41] or in patients with
auto-immune disorders [45] have been described.
At least 26 of the at least 256 DNA Sequence Types recog-
nized within the cosmopolitan Fusarium oxysporum species
complex (FOSC) have been involved in human infection [90].
Recognition of subgroups within FOSC has been restricted to
formae speciales based on host plant specificity. The generalized
name Fusarium oxysporum sensu lato has been used for the
Table 1 Incidence of the different Fusarium species (complexes) in different types of fusarioses, based on different population studies
Geographic location Italy[22] Switzerland[23] Colombia[24] India[25] Mexico[26] France[27] USA[28]
Type of fusariosis Skin/Nail Nail Nail Eye Eye Disseminated All
Species complexes
F. solani SC - FSSC 31 % 33 % 65 % 75 % 82 % 36 % 60 %
F. oxysporum SC - FOSC 34.5 % 56 % 33 % 4 % 6 % 16 % 10 %
G. fujikuroi SC - GFSC 34.5 % 9 % 2 % 9 % 0 37 % 10 %
F. dimerum SC - FDSC 0 2 % 0 9 % 12 % 9 % 5 %
F. chlamydosporum SC - FCSC 0 0 0 0 0 0
15 %
F. incarnatum-equiseti SC - FIESC 0 0 0 3 % 0 2 %
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aggregate. Also, fusarioses caused by members of the FOSC
range from onychomycosis to disseminated infection, but the
latter occurred not only in haemato-oncological [e.g., [57, 58],
but also in SOT [41] and HIV [59] patients, as well as in an
individual suffering from a heatstroke [60].
The Fusarium dimerum species complex (FDSC) contains
at least 12 lineages, of which at least F. dimerum sensu stricto,
F. delphinoides, and F. penzigii have been involved in human
infection [61]. Most case reports on F. dimerum were pub-
lished prior to its recognition as a species complex. Also, in
this species complex the infect ions range from
onychomycoses, keratitis, and other localized infections to
disseminated infections in haemato-oncological patients.
Fusarium chlamydosporum has been named after its fast
and abundant production of thick-walled chlamydo-
spores in mycelium as well as in macroconidia [7]. The
Fusarium chlamydosporum species complex (FCSC)
(F. chlamydosporum sensu lato) contains at least four
distinct species [28]. The complex has only once been im-
plicated in a keratitis [54], but more often in onychomycoses,
cutaneous and deep localized infections, and in disseminated
infections in haemato-oncological patients [28, 35, 64].
Within the Fusarium incarnatum-equiseti species
complex (FIESC) and using four loci, at least 28 spe-
cies can be recognized, which are organized into two
main clades [28]. Haplotypes 1−14 [28] are molecular
siblings of F. equiseti, while the remaining species are
grouped as ‘F. incarnatum’ or ‘F. semitectum’ [7, 28].
Representatives of the two groups have repeatedly been
involved in onychomycoses, skin, eye, and deep local-
ized and disseminated infections, especially in leukemic
patients.
The two members of the Fusarium fujikuroi species
complex (FFSC) that are most commonly observed in
human infections are F. proliferatum and F. verticillioides.
However, members of FFSC are increasingly identified in
especially invasive and disseminated infections in haemato-
oncological patients (Table 2). Many environmental
Fusarium species and the human infections they cause have
a worldwide distribution (Table 2). However, some species
of FFSC species, e.g., F. acutatum, F. anthophilum,
F. andiyazi, F. nygamai, and F. sacchari have a limited
geographic distribution and/or are associated with specific
climatic conditions. For some of the species, distributions
Table 2 Clinical spectrum and the geographical occurrence of the dif-
ferent etiological agents found within the genus Fusarium, based on case
report and population study data. In light grey are infections that have
only been described in a single case report or single population study; in
dark grey are the more frequent infections
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of environmental and clinical strains are concordant (e.g.,
F. andiyazi, F. subglutinans, and F. thapsinum), whereas in
others the reported clinical cases indicate an expansion
outside previously known borderlines (e.g., F. acutatum
and F. napiforme). Fusarium nygamai, known from hot
and arid climates, caused a disseminated infection in a
patient from The Netherlands in Northern Europe, but this
infection was presumably contracted during a recent holi-
day in Egypt [75].
Fusarium sporotrichioides is closely related to Fusarium
poae and F. langsethiae and is located in the Gibberella-clade
of Fusarium [91]. The species is known to produce T-2 and
HT-2 mycotoxins [91], and thus far, two localized infections
have been described: an ulcerative dermatitis [92], and a pedal
lesion in a diabetic [93].
Outside the above-described species complexes, a few
other Fusarium species have been implicated in humans and
other mammals. A strain of F. avenaceum caused an infection
of the claw of a dog, finally leading to osteomyelitis [94]. Both
F. lateritium and F. polyphialidicum were recorded causing
keratitis [54, 95], while F. lateritium also caused a dissemi-
nated infection in an HIV-patient [96].
Conclusions
Within the group of fungi we elect to call Fusarium,
many species and species complexes have been involved
in opportunistic human infections. Species recognition by
morphological characters is difficult, as strains may be
slow in forming distinguishing structures and in particu-
lar, clinical isolates may be pionnotal. Observed
fusarioses range from onychomycoses, skin infections
and keratitis, mainly in healthy individuals, to deep local
and disseminated infections in the immunocompromised.
The disseminated infections predominately occur espe-
cially in leukemic patients and have a high mortality
rate. Many of the opportunistic species complexes seem,
in principle, able to cause the whole range of fusariosis
types. However, significant differences exist in the main
species complexes in classes of infections observed lo-
cally (Table 1).
An important question is whether we need to identify
the etiological agent of a fusariosis to the species level. In
general, as many other members of the order Hypocreales,
Fusarium species are highly refractory to antifungal ther-
apy. Only few antifungal drugs—amphothericin,
voriconazole and terbinafine—seem effective [89], and
variation can be observed between and within species
and species complexes [e.g., [25, 29, 48, 67]. To reveal
small differences in susceptibility between clinically rele-
vant Fusarium species, precise identification of siblings is
recommended.
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